Published: 05 August, 2018 | Volume 2 - Issue 1 | Pages: 029-048
In 1874 J.M. Charcot was the first to describe ALS amyotrophic lateral sclerosis, a disease with an high non response therapy rate also to the actual therapy.
ALS is not clearly associate to only single etio-patogenetic movens but many process seem involved.
Also the strange geographic diffusion of different forms contribute to a complex syndromic pathology.
The introducing of new theories and approach can help to find more efficacy therapeutic strategies.
In this work the different neuronal damage movens and new therapeutic strategies are analyzed to produce a Unic global response to the pathologic process useful in next clinical application.
Genetic factors must be considered also added to environmental movens but also to the endogenous microenvironment of motoneuron involved.
A toxicological-biochemical-imunological approach can be useful tool to find new therapeutic strategies.
Or to improve local availability of pharmacological molecules.
ALS; Amyotrophic lateral sclerosis; Etiology; Pathology; Endogenous esogenous factors
HSPI: We're glad you're here. Please click "create a new Query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."